Paloma Partners’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-32,292
| Closed | -$628K | – | 2476 |
|
|
2018
Q1 | $628K | Sell |
32,292
-1,052
| -3% | -$20.6K | 0.01% | 1245 |
|
|
2017
Q4 | $555K | Buy |
+33,344
| New | +$611K | 0.01% | 1303 |
|
|
2017
Q2 | – | Sell |
-57,730
| Closed | -$730K | – | 2569 |
|
|
2017
Q1 | $730K | Buy |
57,730
+3,156
| +6% | +$38.1K | 0.01% | 1429 |
|
|
2016
Q4 | $723K | Buy |
54,574
+38,627
| +242% | +$660K | 0.01% | 1340 |
|
|
2016
Q3 | $378K | Buy |
15,947
+4,836
| +44% | +$130K | ﹤0.01% | 1530 |
|
|
2016
Q2 | $320K | Buy |
+11,111
| New | +$362K | ﹤0.01% | 1735 |
|
|
2016
Q1 | – | Sell |
-8,136
| Closed | -$348K | – | 2190 |
|
|
2015
Q4 | $348K | Sell |
8,136
-8,787
| -52% | -$351K | 0.01% | 1249 |
|
|
2015
Q3 | $596K | Buy |
16,923
+12,277
| +264% | +$553K | 0.01% | 943 |
|
|
2015
Q2 | $213K | Sell |
4,646
-8,661
| -65% | -$411K | ﹤0.01% | 1534 |
|
|
2015
Q1 | $624K | Sell |
13,307
-17,222
| -56% | -$685K | 0.02% | 690 |
|
|
2014
Q4 | $967K | Buy |
+30,529
| New | +$893K | 0.04% | 444 |
|
|
2014
Q2 | – | Sell |
-8,538
| Closed | -$226K | – | 1308 |
|
|
2014
Q1 | $226K | Buy |
+8,538
| New | +$213K | 0.01% | 563 |
|
|
2013
Q4 | – | Sell |
-17,300
| Closed | -$355K | – | 1267 |
|
|
2013
Q3 | $355K | Buy |
+17,300
| New | +$357K | 0.01% | 590 |
|
Paloma Partners's IPXL Position: Q2 2018 in Review
Paloma Partners sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 32,292 shares — an estimated $628K sold.
Paloma Partners first reported a position in IPXL in Q3 2013 and held it in 13 quarters. The position peaked at $967K in Q4 2014. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- Paloma Partners reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- Paloma Partners sold 32,292 Impax Laboratories, Inc. shares in Q2 2018, an estimated $628K.
- Paloma Partners first reported a position in Impax Laboratories, Inc. in Q3 2013 and held it in 13 quarters.
- Paloma Partners's Impax Laboratories, Inc. position peaked at $967K in Q4 2014.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on Paloma Partners's 13F filing for Q2 2018, filed 14 Aug 2018.